259 filings
Page 6 of 13
DEFA14A
ctanr6
29 Apr 20
Additional proxy soliciting materials
7:32am
8-K
ksgi 8wgv
7 Apr 20
Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline
4:25pm
8-K
0u8mpy2f9g 4uyl85
18 Mar 20
Sage Therapeutics Announces Development Plan for Zuranolone(SAGE-217) Following
6:57am
S-8
6nb7 sfyq
27 Feb 20
Registration of securities for employees
7:32am
8-K
p7klv
27 Feb 20
Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
tc44hqny3wz0dr 2m565
5 Dec 19
Sage Therapeutics Reports Topline Results from Pivotal Phase 3
7:01am
8-K
rw8 o4zie23lj
12 Nov 19
Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights
6:44am
8-K
6yvv34 zlcc
6 Aug 19
Results of Operations and Financial Condition
7:04am
8-K
b8hx cgpj38
24 Jul 19
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline
7:18am
8-K
ceplriv1c7vh3c
14 Jun 19
Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSOâ„¢ (brexanolone) Injection
9:03am
8-K
o2frzniad1p6b1tyq7s
6 Jun 19
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
0ce08ewrhqe1h 5w88dy
2 May 19
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
7:25am
DEFA14A
acg7202x4vns6lx xn8d
25 Apr 19
Additional proxy soliciting materials
4:04pm